Harrow, Inc. (NASDAQ:HROW) Receives $71.14 Average Price Target from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have earned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $71.1429.

HROW has been the topic of a number of research analyst reports. Nomura cut Harrow to a “neutral” rating in a research report on Wednesday. William Blair reissued an “outperform” rating on shares of Harrow in a research report on Tuesday, March 3rd. HC Wainwright raised their price target on Harrow from $69.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Cantor Fitzgerald cut their price target on Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Finally, Zacks Research cut Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 3rd.

Institutional Trading of Harrow

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Harrow by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock worth $94,162,000 after purchasing an additional 50,889 shares during the period. Geode Capital Management LLC increased its stake in Harrow by 4.7% in the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock valued at $24,765,000 after purchasing an additional 36,724 shares during the period. Marshall Wace LLP raised its holdings in shares of Harrow by 31.5% in the second quarter. Marshall Wace LLP now owns 564,876 shares of the company’s stock valued at $17,251,000 after buying an additional 135,202 shares during the last quarter. Penn Capital Management Company LLC raised its holdings in shares of Harrow by 20.5% in the fourth quarter. Penn Capital Management Company LLC now owns 392,067 shares of the company’s stock valued at $19,257,000 after buying an additional 66,589 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Harrow by 32.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 370,548 shares of the company’s stock worth $18,159,000 after buying an additional 90,331 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $34.48 on Friday. Harrow has a 12 month low of $20.85 and a 12 month high of $54.85. The firm has a market capitalization of $1.28 billion, a P/E ratio of -202.81 and a beta of 0.05. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06. The company’s fifty day moving average price is $45.14 and its 200 day moving average price is $43.55.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.